Bio­mea Fu­sion stock soars on ear­ly-stage di­a­betes da­ta

Red­wood City, CA-based Bio­mea Fu­sion saw about a 50% in­crease in its stock to­day af­ter re­veal­ing ear­ly da­ta for its co­va­lent menin in­hibitor, BMF-219, for the treat­ment of type 2 di­a­betes.

Da­ta from two co­horts en­rolled in the Phase II por­tion of its on­go­ing Phase I/II clin­i­cal study showed po­ten­tial for the in­hibitor to “re­lease the brakes” of “re­gen­er­a­tion, re­ac­ti­va­tion, and preser­va­tion” of be­ta cells, Bio­mea re­port­ed. Be­ta cells have to work hard­er in peo­ple with type 2 di­a­betes in or­der to pro­duce enough in­sulin to low­er blood sug­ar lev­els, lead­ing to the loss or weak­en­ing of the cells.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN